The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.
The study demonstrates that Veracyte's new test improves upon an earlier version in its ability to identify thyroid nodules that are likely to be benign.
Pilot participants have access to a version of Clear Labs' sequencing and analysis platform that is designed for high-volume food safety and quality testing.
